207_Combined course Presentations
Rationale for integrating Sunitinib and PCI in ED-SCLC
The potential for synergy between PCI and sunitinib is supported by both preclinical and clinical reports.
It has previously been established that small cell lung cancer expresses vascular endothelial growth factor ( VEGF ) receptors and that VEGF is required for the development of brain metastases . In murine models , the delivery of antiangiogenic agents alone to the brain has been shown to slow the growth of brain metastases . Sunitinib seems to have a “single-agent activity” against brain metastases also in human models.
Made with FlippingBook